menu search

Pipeline moves: approval prospects rise for oesophageal cancer drug after trial completion

On a good note, we investigate the completion of a Phase IIb trial in congestive heart failure and chronic kidney disease, a Phase II trial in triple-...

November 2, 2023, 8:29 pm

Merck's keytruda shows positive results in confirmatory trial as treatment for rare form of esophageal cancer

Merck & Co. MRK, -1.53% said Friday a late-stage trial of its blockbuster cancer drug Keytruda plus trastuzumab, fluoropyrimidine- and platinum-contai...

October 20, 2023, 8:13 am

Alx oncology: on right track with latest interim analysis of evorpacept

ALX Oncology reported positive interim results from its phase 2 study using its anti-CD47 drug for HER2-positive gastric/gastr...

October 9, 2023, 12:38 am

Alx oncology stock doubles on early data from phase ii cancer trial

ALX Oncology Holdings Inc saw its stock value double in pre-market trading on the heels of promising interim data from a phase II study assessing th...

October 3, 2023, 8:47 am

Leap therapeutics to present updated data from part a of the distinguish study of dkn-01 plus tislelizumab and chemotherapy in gastric cancer patients at the 2023 asco annual meeting

19.5 months median OS in the overall first-line patient population, exceeding current benchmarks Long-term follow-up identifies additional patient wit...

May 25, 2023, 5:10 pm

Merck's (mrk) keytruda sbla accepted by fda for gastric cancer

Merck's (MRK) application seeking approval for Keytruda in combination with fluoropyrimidine- and platinum-containing chemotherapy for the early treat...

April 14, 2023, 3:12 pm

Zymeworks shares gain on promising data for cancer drug in development with jazz pharmaceuticals

Shares of Zymeworks Inc. ZYME, rallied 14% in premarket trading on Thursday after the company and Jazz Pharmaceuticals Inc. JAZZ, -0.58% said their ex...

January 19, 2023, 8:07 am

Phathom pharmaceuticals announces positive topline results from phase 3 phalcon-nerd-301 trial evaluating daily dosing of vonoprazan for symptomatic non-erosive gastroesophageal reflux disease (nerd)

Both vonoprazan 10 mg and 20 mg doses met the primary endpoint and showed highly statistically significant greater percentage of 24-hour heartburn fre...

January 8, 2023, 11:00 pm

Phathom pharmaceuticals reports third quarter 2022 financial results and provides business updates

Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosin...

November 8, 2022, 10:00 pm

Leap therapeutics to present new data from distinguish study of dkn-01 plus tislelizumab and waking study of dkn-01 plus tecentriq® at the esmo congress

Median Progression-Free Survival of 11.3 months in first-line gastric cancer patients treated with DKN-01 plus tislelizumab and CAPOX, exceeding bench...

September 4, 2022, 6:05 pm

Phathom pharma's digestive disease candidate meets primary goal in mid-stage study

Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episod...

February 10, 2022, 10:02 am

Phathom pharma's digestive disease candidate meets primary goal in mid-stage study

Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episod...

February 10, 2022, 10:02 am

Phathom pharma's digestive disease candidate meets primary goal in mid-stage study

Phathom Pharmaceuticals Inc PHAT reported topline results from the PHALCON-NERD Phase 2 study of vonoprazan as an on-demand therapy to relieve episod...

February 10, 2022, 10:02 am


Search within

Pages Search Results: